CaRi-heart technology
Revolutionary new technology to assess the risk of a serious heart condition or heart attack – many years before anything happens.
HCA UK’s London Bridge Hospital offers amyloid-targeting therapies for the treatment of early-stage Alzheimer's disease
London, UK, 6th March 2025: Leading private healthcare provider HCA Healthcare UK has announced that it is offering amyloid-targeting therapies for patients diagnosed with early-stage Alzheimer's disease. The therapies available include lecanemab and donanemab - the first two disease-modifying treatments for Alzheimer’s disease licensed for use in Great Britain.
Amyloid-targeting therapies have been shown to modestly slow the rate of progression in patients with mild cognitive impairment or early-stage dementia caused by Alzheimer’s disease.
This announcement from HCA UK comes after the MHRA approval of lecanemab (under the brand name LEQEMBI®) in August 2024 and donanemab (under the brand name of Kisunla™ in October 2024. Both lecanemab and donanemab are now available to self-pay patients at HCA UK.
The treatment programme, overseen by leading dementia-specialist Consultant Neurologist Dr Johnathan Chan, is carried out HCA UK’s London Bridge Hospital. The course of the treatment is 18 months, during which time patients are continuously monitored by HCA UK’s expert clinical team, from the initial tests through to maintenance treatment.
Both lecanemab and donanemab have been tested in large clinical trials to understand their safety and efficacy in patients with early Alzheimer’s disease. After 18 months of treatment, these therapies slowed the rate of disease progression by up to nearly one third.
HCA UK is one of just a few healthcare providers in the UK currently offering amyloid-targeting therapies. The provision of this therapy is the latest example of HCA UK’s ability to provide complex and highly specialised treatment and care, due to the expertise and clinical infrastructure found within the ‘Outstanding’ London Bridge Hospital and wider HCA UK network.
Janene Madden, Chief Executive Officer at London Bridge Hospital, said:
“We are proud to be one of the first providers in the UK offering new amyloid-targeting therapies for patients diagnosed with early-stage Alzheimer's disease.
“Across HCA Healthcare UK we are committed to actively embracing innovation and the early adoption of effective treatment options such as lecanemab. The introduction of amyloid-targeting therapies at London Bridge Hospital is a positive step in the treatment of early-stage Alzheimer’s disease, helping to shape the future of neurological care, offering new hope and improved outcomes for patients in our care.”
Dr Johnathan Chan, Consultant Neurologist at London Bridge Hospital said:
“As one of the leading private providers of neurological care in the UK, we are thrilled to be able to offer patients diagnosed with early-stage Alzheimer’s disease the latest in effective treatment options to slow the progression of the disease.
“Alzheimer’s is the most common dementia, affecting 60% of cases in the UK. While current treatments only ease symptoms, new licensed drugs can now slow the disease’s progression for certain patients. Clinical trials showed lecanemab reduced cognitive decline by 27% and reduced decline in a patient’s quality of life by up to 56%. Access to treatment programmes, like those now available at London Bridge Hospital, can greatly impact patients’ journeys.”